On November 25, 2019 Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, reported that its President and Chief Executive Officer, Peter L. Hoang, will present at two upcoming investor conferences (Press release, Marker Therapeutics, NOV 25, 2019, View Source [SID1234551675]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details

Piper Jaffray 31st Annual Healthcare Conference
Date: Tuesday, December 3, 2019
Time: 1:00 p.m. EST
Location: New York, NY

Evercore ISI 2nd Annual HealthCONx Conference
Date: Wednesday, December 4, 2019
Time: 11:45 a.m. EST
Location: Boston, MA

Live webcasts of the presentations will be accessible from the investors section of the company’s website at www.markertherapeutics.com and will be available for replay following the event.